Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Clinical trials sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo targets Hard-to-Treat cancers in early trial Results expected Dec 2026 (estimated)
-
Can a Two-Drug combo outsmart resistant lung cancer?
Disease control Recruiting nowThis phase 3 trial is testing whether a combination of two targeted drugs, ASKC202 and limertinib, can help people with advanced non-small cell lung cancer (NSCLC) whose tumors have a specific genetic change (MET amplification/overexpression) and have stopped responding to earlie…
Phase 3 • Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a new antibiotic outmatch an old one against Drug-Resistant pneumonia?
Disease control Recruiting nowThis trial is testing an experimental antibiotic called ASK0912 against an older drug, polymyxin B, in adults with hospital-acquired or ventilator-associated pneumonia caused by multidrug-resistant bacteria. Participants will receive one of two dosing schedules of ASK0912 or the …
Phase 2 • Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called ASKC202, given alone or with another drug (ASK120067), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. A…
Phase 1 • Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC